Vetoquinol Review: Product Labels, Studies and Quality Systems

The manufacturer shop supplies omega and calming-product quantities missing from corporate overviews. Public experts and quality disclosures also need their proper scope.

By La Petite Labs Editorial 8 min read

As Seen On

  • AVMA, American Veterinary Medical Association
  • Today’s Veterinary Business
  • Petfood Industry
Pet Gala™ Skin & Coat Supplement

15 science-backed barrier actives

From$43/moSave up to 47%Save up to 46%Shop Now
Contents
Evidence checked November 11, 2026

Disclosure: La Petite Labs publishes this review and sells its own pet supplements.

This review corrects the missing EPA/DHA, incomplete Zylkene-label, unnamed-expert and absent-facility characterizations, and distinguishes ingredient research from finished formulas. Evidence was checked November 11, 2026. Current shop pages and July 2026 additions are not treated as proof of what every page said at the original review date.

Scope and what changed

This review covers the US Flexadin Advanced, Triglyceride OMEGA and Zylkene supplement families. Vetoquinol's corporate overviews, manufacturer shop and group annual report contain different parts of the public record. The earlier review overstated missing-label and unnamed-expert claims after relying too heavily on the overview pages.

Labels and quantities

The Triglyceride OMEGA 8 fl oz liquid pump lists 1,000 mg fish oil, at least 180 mg EPA and 120 mg DHA per 1 mL pump. Classic Zylkene labels disclose 75, 225 or 450 mg of hydrolyzed bovine milk protein providing alpha-casozepine per capsule, together with inactive ingredients. The protein-hydrolysate amount must not be described as an equal quantity of isolated alpha-casozepine. Flexadin Advanced lists 40 mg UC-II and 10 mg total undenatured collagen; Extra Strength lists 80 mg and 20 mg respectively per 3 g chew. The current Zylkene Plus 450 mg shop page contains an inconsistent serving panel, so buyers should use the exact package panel rather than combine strengths or assume that the campaign supplies a reliable complete label for every variant.

Research and its limits

Flexadin cites D'Altilio 2007 for the UC-II ingredient. That citation should not be presented as proof that every current Flexadin formula was tested. The Zylkene campaign lists Beata 2007 on Zylkene and Porcheron 2023 on a combination with white-fish hydrolysate; the current Zylkene Plus 225 mg shop page also cites Porcheron. Classic Zylkene and Zylkene Plus are different formulas. Some corporate claims use clinical-style language without a directly matching citation on the same page, so the research needs product-specific interpretation.

Named expert roles

The April 2025 VeRBS announcement identifies credentialed veterinary educators, including Duncan Lascelles and Marie Bartling, and explains their rehabilitation-education roles. A July 2026 article identifies Acacia Roman, DVM, as a Technical Services Veterinarian. These are disclosed expert roles, not evidence that those individuals formulated every supplement. The July article postdates the original review and is credited as a current addition.

Manufacturing, testing and public reports

Vetoquinol describes NASC auditing, facility requirements and adverse-event reporting on its US site. The 2025 group report describes raw-material and finished-product release controls and identifies manufacturing sites including Lure/Magny-Vernois and Tarare. It distinguishes Tarare's nonmedicinal production from the GMP sites. Those disclosures should not become a claim that every US supplement carries every group certification. The reviewed sources did not supply a lot-specific analytical report or identify the laboratory for each sampled US supplement. Group quality systems and buyer-visible lot results answer different questions.

Declared sample: Flexadin Advanced UC-II 40 mg chew; Flexadin Advanced Extra Strength UC-II80 mg/3 g chew; Triglyceride OMEGA8 fl oz liquid pump,1 mL serving; Zylkene classic75/225/450 mg capsules; Zylkene Plus225/450 campaign label disclosures checked as a current-version contradiction.

Public transparency score

Public transparency: 75/100 — Solid With Gaps. This score uses the existing 2026.2 rubric and the declared sample below. It does not measure safety, efficacy or clinical superiority.

CriterionScoreWeightEvidence and limits
Label And Dose Transparency8/1015%The liquid pump lists1,000 mg fish oil, at least180 mg EPA and120 mg DHA per1 mL, plus vitamin quantities. Classic Zylkene lists75/225/450 mg hydrolyzed bovine milk protein providing alpha-casozepine, and Flexadin lists its UC-II and undenatured-collagen amounts. The hydrolyzed-protein quantity is not isolated alpha-casozepine mass. The directly retrieved current Zylkene Plus450 shop panel states a0.250 g capsule containing450 mg milk hydrolysate and omits the fish-hydrolysate amount despite describing it as an ingredient. This secondary-product inconsistency prevents near-complete disclosure credit.
Scientific Rationale Disclosure6/1010%The product family pages explain UC-II collagen, fish-oil omega roles and the milk-derived calming ingredient, but the explanations are dispersed and some are mainly benefit statements. Meaningful ingredient logic is public, but the reviewed pages do not explain the biology of every meaningful active consistently. This retains tier6 on a fresh review, rather than treating the original score as verified.
Evidence And Clinical Citation Transparency7/1015%Flexadin cites D'Altilio2007. The Zylkene campaign supplies Beata2007 and Porcheron2023 references, rather than having no research. The UC-II trial is ingredient-specific; Porcheron concerns the combination with white-fish hydrolysate and cannot be transferred automatically to classic Zylkene. Some corporate clinical claims lack a direct matching citation. This fits uneven citation/ingredient borrowing, not an absence of trials.
Veterinary And Expert Transparency9/1015%A July2026 article identifies Acacia Roman,DVM,Technical Services Veterinarian. The April2025 VeRBS announcement names credentialed educators including Duncan Lascelles and Marie Bartling and states their rehabilitation-education scope. Technical service and education are actual disclosed roles; no claim is made that these people formulated every supplement. Full primary-navigation biographical coverage needed for10 was not established.
Testing And COA Transparency6/1015%The2025 group report describes raw-material and finished-product control/release and environmental compliance; the US NASC page describes auditing and adverse-event systems. This is meaningful quality/testing information, not generic marketing alone. The group-level report does not connect each sampled US supplement to a named analytical laboratory, tested panel or buyer-visible lot result. An equine-only named-lab program found separately is not transferred to this sample.
Manufacturing And Quality-System Transparency9/1010%The2025 report identifies production sites including Lure/Magny-Vernois and Tarare and describes site-dependent quality systems. The US site separately identifies NASC auditing and cGMP requirements. The report expressly distinguishes nonmedicinal Tarare from GMP plants. It does not establish that every supplement has every group certification, nor does it map each sampled SKU to its factory. Facility and system disclosure is strong but incomplete at that resolution.
Claim Discipline And Consumer Honesty7/1010%Joint and calming marketing includes clinical-style language while cited research varies by ingredient/formula. Zylkene Plus provides a published real-world-evidence citation but bases its proven-palatability claim on data on file, which buyers cannot inspect from the page. This scores uneven public qualification, not whether the products work. The liquid's actual EPA/DHA panel is recognized rather than incorrectly called absent.
Accessibility And Buyer Verifiability8/1010%Corporate navigation exposes product and NASC pages, and links the group site; label detail is public on the manufacturer shop. Expert news and the annual report require deeper navigation across these official properties. One or two evidence pillars are dispersed/deeper rather than in a single three-click trust hub. The indexed campaign has a failed direct fetch, recorded as an access limitation rather than proof that the cited study does not exist.

Owner reviews and price

Owner comments can help with palatability and serving practicality, but cannot verify an effect or compare clinical performance. The earlier June 2026 price search did not establish an exact current pack price. The manufacturer shop now supplies purchase options for some products; compare the selected pack and serving directions before calculating daily cost. This review does not carry forward an unverified marketplace rating or an all-product price claim.

Where La Petite Labs fits

Triglyceride OMEGA and Pet Gala differ in composition. The Vetoquinol liquid publishes separate EPA and DHA amounts; Pet Gala's omega mixture is grouped. This review does not establish Pet Gala's clinical superiority or interchangeability with Vetoquinol's joint or calming products. Product choice requires the exact formula and intended purpose, not a broad brand preference.

Review conclusion

Vetoquinol publishes more label detail, named veterinary involvement and manufacturing information than the earlier review credited. Meaningful limits remain: research applies to particular ingredients or formulas, some pages require cross-checking, and group disclosures do not supply individual-lot results. Those limits do not support a claim that products are untested or clinically inferior to La Petite Labs.

FAQ

Is Vetoquinol USA legit?

This review covers the US Flexadin Advanced, Triglyceride OMEGA and Zylkene supplement families. Vetoquinol's corporate overviews, manufacturer shop and group annual report contain different parts of the public record. The earlier review overstated missing-label and unnamed-expert claims after relying too heavily on the overview pages.

What is the bottom line of this Vetoquinol USA review?

Vetoquinol publishes more label detail, named veterinary involvement and manufacturing information than the earlier review credited. Meaningful limits remain: research applies to particular ingredients or formulas, some pages require cross-checking, and group disclosures do not supply individual-lot results. Those limits do not support a claim that products are untested or clinically inferior to La Petite Labs.

What does the Vetoquinol USA transparency score measure?

The public-transparency score is 75/100 under the published eight-criterion rubric. It measures disclosed evidence for the declared sample, not safety, efficacy, product suitability or clinical superiority.

Does Vetoquinol USA publish COAs?

Vetoquinol describes NASC auditing, facility requirements and adverse-event reporting on its US site. The 2025 group report describes raw-material and finished-product release controls and identifies manufacturing sites including Lure/Magny-Vernois and Tarare. It distinguishes Tarare's nonmedicinal production from the GMP sites. Those disclosures should not become a claim that every US supplement carries every group certification. The reviewed sources did not supply a lot-specific analytical report or identify the laboratory for each sampled US supplement. Group quality systems and buyer-visible lot results answer different questions.

Does Vetoquinol USA name veterinarians or experts?

The April 2025 VeRBS announcement identifies credentialed veterinary educators, including Duncan Lascelles and Marie Bartling, and explains their rehabilitation-education roles. A July 2026 article identifies Acacia Roman, DVM, as a Technical Services Veterinarian. These are disclosed expert roles, not evidence that those individuals formulated every supplement. The July article postdates the original review and is credited as a current addition.

What are the biggest pros of Vetoquinol USA?

EPA and DHA quantities for the liquid pump; Named veterinary technical and education roles; Public group manufacturing and quality-system disclosures.

What are the biggest cons of Vetoquinol USA?

A current Zylkene Plus campaign label has inconsistent serving information; Studies concern different ingredients and formulas; Group quality disclosures do not identify the lab report for an individual US supplement lot.

How should I use Vetoquinol USA customer reviews?

Customer reviews can describe taste, serving practicality and owners' experiences. They do not verify the active quantities, establish causation, or demonstrate clinical superiority.

Is Pet Gala a replacement for Vetoquinol USA?

Triglyceride OMEGA and Pet Gala differ in composition. The Vetoquinol liquid publishes separate EPA and DHA amounts; Pet Gala's omega mixture is grouped. This review does not establish Pet Gala's clinical superiority or interchangeability with Vetoquinol's joint or calming products. Product choice requires the exact formula and intended purpose, not a broad brand preference.

Who is Vetoquinol USA best for?

Choose the exact formula for the intended purpose and the animal's circumstances. Check its ingredient quantities, serving directions, cautions and relevant evidence. The brand score alone does not determine an appropriate product.

What is the main label issue with Vetoquinol USA?

The Triglyceride OMEGA 8 fl oz liquid pump lists 1,000 mg fish oil, at least 180 mg EPA and 120 mg DHA per 1 mL pump. Classic Zylkene labels disclose 75, 225 or 450 mg of hydrolyzed bovine milk protein providing alpha-casozepine per capsule, together with inactive ingredients. The protein-hydrolysate amount must not be described as an equal quantity of isolated alpha-casozepine. Flexadin Advanced lists 40 mg UC-II and 10 mg total undenatured collagen; Extra Strength lists 80 mg and 20 mg respectively per 3 g chew. The current Zylkene Plus 450 mg shop page contains an inconsistent serving panel, so buyers should use the exact package panel rather than combine strengths or assume that the campaign supplies a reliable complete label for every variant.

How does Vetoquinol USA compare with La Petite Labs?

Triglyceride OMEGA and Pet Gala differ in composition. The Vetoquinol liquid publishes separate EPA and DHA amounts; Pet Gala's omega mixture is grouped. This review does not establish Pet Gala's clinical superiority or interchangeability with Vetoquinol's joint or calming products. Product choice requires the exact formula and intended purpose, not a broad brand preference.

Sources reviewed

Primary manufacturer sources were checked on November 11, 2026. Linked documents have the dates and limits stated in the review. Some manufacturer pages were available through a public search index while direct automated requests failed; such failures were not treated as proof of missing evidence. Manufacturer program descriptions were not independently audited.